Skip to content
PICO PortalSearch builder

Strategy check

Check of an existing strategy

DoneStarted Oct 28, 2026, 18:02 UTCFinished Oct 28, 2026, 18:03 UTC

Stages

  1. Reading the strategy(done)
  2. Checking MeSH(done)
  3. Counting in PubMed(done)
  4. Run Search(done)
  5. Saving(done)
Run log (9)
  1. Reading the strategy: Reading the numbered search lines
  2. Checking MeSH: Checking 1 vocabulary term against NLM MeSH
  3. Counting in PubMed: Running 3 lines on PubMed
  4. Line 1: 204,451 records
  5. Line 3: 1,740 records
  6. Line 2: 5,792 records
  7. Run Search: Fetching the first 20 records of line 3
  8. Saving: Saving the run
  9. Finished.

Final count (line 3)

1,740

Open in PubMed (opens in a new tab)
Query as run (59 characters)("Diabetes Mellitus, Type 2"[Mesh]) AND (semaglutide[tiab])

Search lines

Vocabulary terms are marked ✓︎ valid, ↪︎ mapped to the preferred heading, ✗︎ not found, ⚠︎ not checked.
Numbered search lines with their PubMed counts and the counts reported in the document
No.SearchResults(reported)
1"Diabetes Mellitus, Type 2"[Mesh] (MeSH heading valid: D003924)204,451no reported count
2semaglutide[tiab]5,792no reported count
3Final1 AND 21,740no reported count

Issues

No issues found.

First records

The first 20 of the final line's records, as PubMed sorts them.
  1. Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database. (PubMed, opens in a new tab)

    Yildirim BO, Sarkim IF, Yalman G et al. · BMC cardiovascular disorders · 2026 · PMID 42947001

  2. Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance. (PubMed, opens in a new tab)

    Melamed B, Parsi-Zahabi M, Omrani MA et al. · Pharmacoepidemiology and drug safety · 2026 · PMID 42946127

  3. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis. (PubMed, opens in a new tab)

    Alfawaz M, Bajamaan D, Alghamdi L et al. · Medicine · 2026 · PMID 42937793

  4. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications. (PubMed, opens in a new tab)

    Jang R, Jang M, Ruan X et al. · European journal of clinical pharmacology · 2026 · PMID 42918905

  5. Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies. (PubMed, opens in a new tab)

    Kounatidis DC, Vallianou NG, Kouveletsou M et al. · Current obesity reports · 2026 · PMID 42905300

  6. Effectiveness of Weekly Semaglutide Treatment (0.5 or 1 mg) in Chilean Patients with Type 2 Diabetes Mellitus. (PubMed, opens in a new tab)

    Estica M, Godoy G, Vargas C et al. · Revista medica de Chile · 2026 · PMID 42899606

  7. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis. (PubMed, opens in a new tab)

    Rasool ZK, Shah R, Batool AEZ et al. · Frontiers in endocrinology · 2026 · PMID 42890523

  8. Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study. (PubMed, opens in a new tab)

    Khojah AA, Gazzaz MJ, Aldurdunji MM et al. · The Libyan journal of medicine · 2026 · PMID 42886550

  9. Glucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity. (PubMed, opens in a new tab)

    Governor SB, Dávila-García DM, Rivera-Segarra E et al. · Journal of the American Heart Association · 2026 · PMID 42885796

  10. Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review. (PubMed, opens in a new tab)

    González-Cruz DC, Garcia-Campa M, Moreno-Peña PJ et al. · BMJ medicine · 2026 · PMID 42866418

  11. Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports. (PubMed, opens in a new tab)

    Wu Y, Li K, Wang Y et al. · Frontiers in endocrinology · 2026 · PMID 42865361

  12. Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report. (PubMed, opens in a new tab)

    Niknam K, Niknam T · International medical case reports journal · 2026 · PMID 42859665

  13. Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease. (PubMed, opens in a new tab)

    Gong C, Luo Q, Li Q · Medicine · 2026 · PMID 42854065

  14. Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions. (PubMed, opens in a new tab)

    Hafez A, Nour M, Ibrahim R et al. · Current cardiology reports · 2026 · PMID 42827168

  15. Predictors of treatment response to semaglutide for weight management. (PubMed, opens in a new tab)

    Tzoulis P · Frontiers in endocrinology · 2026 · PMID 42824923

  16. Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues. (PubMed, opens in a new tab)

    Popa Ilie IR, Ghibu S, Butuca A et al. · BMJ open · 2026 · PMID 42823110

  17. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. (PubMed, opens in a new tab)

    Singhani V, Ehsan M, Valencia S et al. · Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026 · PMID 42808923

  18. Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes. (PubMed, opens in a new tab)

    Hoog MM, Vallarino C, Maldonado JM et al. · Journal of managed care & specialty pharmacy · 2026 · PMID 42808550

  19. Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia. (PubMed, opens in a new tab)

    Alharajin R, AlTaweel M, AlSubaiee M et al. · Journal of the ASEAN Federation of Endocrine Societies · 2026 · PMID 42802824

  20. Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study. (PubMed, opens in a new tab)

    Ferician AC, Ghitea TC, Popoviciu MS · Medicina (Kaunas, Lithuania) · 2026 · PMID 42796421

Export

Strategy (.txt)PMIDs (.txt)MEDLINE (.txt)Provenance (.json)

The strategy file has the numbered lines with counts, the search date and the AI-use statement. PMIDs and MEDLINE are fetched from PubMed when you download, so they reflect PubMed today.

Checking PubMed for the current list of PMIDs…